Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 47,648 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 47,648 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $5.06, for a total transaction of $241,098.88. Following the sale, the insider owned 409,815 shares in the company, valued at $2,073,663.90. This represents a 10.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, January 20th, Los Pinos Elisabet De sold 16,928 shares of Aura Biosciences stock. The stock was sold at an average price of $4.86, for a total value of $82,270.08.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $5.25 on Wednesday. The business’s 50 day moving average is $5.60 and its two-hundred day moving average is $5.97. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $8.03. The stock has a market capitalization of $333.38 million, a P/E ratio of -2.71 and a beta of 0.46.

Analyst Ratings Changes

AURA has been the subject of several recent analyst reports. Evercore began coverage on shares of Aura Biosciences in a research note on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Aura Biosciences has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in AURA. Frazier Life Sciences Management L.P. bought a new position in shares of Aura Biosciences in the second quarter worth about $31,926,000. Vanguard Group Inc. lifted its holdings in Aura Biosciences by 16.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock valued at $17,863,000 after buying an additional 413,001 shares in the last quarter. Franklin Resources Inc. boosted its position in Aura Biosciences by 5.9% in the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock valued at $14,653,000 after buying an additional 130,221 shares during the period. Nantahala Capital Management LLC grew its stake in Aura Biosciences by 67.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock worth $13,257,000 after acquiring an additional 850,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. grew its stake in Aura Biosciences by 8.8% in the 3rd quarter. Levin Capital Strategies L.P. now owns 1,627,274 shares of the company’s stock worth $10,057,000 after acquiring an additional 131,714 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences News Summary

Here are the key news stories impacting Aura Biosciences this week:

• Neutral Sentiment: Short-interest entries on Feb. 16–17 report a “large/significant increase” but show 0 shares and NaN changes, indicating likely data/reporting errors rather than genuine new short activity. This is an uncertain/neutral factor.
• Negative Sentiment: Insider sale — Los Pinos Elisabet De (insider) sold 47,648 shares at an average ~$5.06 (reducing her stake ~10.42%). SEC filing: Los Pinos Elisabet De sale
• Negative Sentiment: Insider sale — Amy Elazzouzi (SVP) sold 8,549 shares at an average ~$5.06 (reducing her stake ~10.17%). SEC filing: Amy Elazzouzi sale
• Negative Sentiment: Insider sale — Janet Jill Hopkins sold 20,401 shares at an average ~$5.06 (reducing her stake ~8.07%). SEC filing: Janet Jill Hopkins sale
• Negative Sentiment: Insider sale — Mark Plavsic (CTO) sold 15,890 shares at an average ~$5.05 (reducing his stake ~8.05%). SEC filing: Mark Plavsic sale
• Negative Sentiment: Insider sale — Conor Kilroy sold 12,079 shares at an average ~$5.05 (reducing his stake ~6.74%). SEC filing: Conor Kilroy sale

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.